Funding Details
- Awarder
- StartEngine
- Date Award
- March 26, 2022
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Valuation
-
$39,000,000
Company Info
- Founding Year
- 1999
- Traction
- Many common life-threatening diseases require dangerous treatments that have long-lasting side-effects or few options. Patients suffering from Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), Parkinson’s disease (PD), and COVID-19 are faced with either the reality of no realistic treatment options or potentially harmful and painful treatments with long-lasting side-effects.
- Organizations Involved
- Rutgers University, Novartis Pharmaceuticals, Vertical Spine, LLC., Cascade Medical Enterprises, Integrated Communications Corp. (ICC/IPG), Englewood Hospital and Medical Center, Mount Sinai School of Medicine
- Founders
- Prof. Richard L. Chang, Ben Chang, Sean M. O’Connell, Ph.D.
- Company Description
- PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. They are working to utilize gene therapy to treat diseases, allowing the body to heal, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s disease, and viruses.
- Market
- Genomic Medicine
- Location
-
Century City,
CA,
US
- Coinvestors
- StartEngine Capital, LLC
Links